Datasets:

armanc

/

pubmed-rct20k

like 0

24412457

results

Procedural success was achieved in all patients .

24412457

results

At late angiography ( median @ days ; @ % of eligible patients ) , patients in the EES arm had a significantly larger minimal lumen diameter ( @ @ mm vs. @ @ mm , p < @ ; absolute mean difference : @ mm ; @ % confidence interval -LSB- CI -RSB- : @ to @ ) and a lower percent of diameter stenosis ( @ @ % vs. @ @ % , p < @ ) .

24412457

results

However , late loss ( @ @ mm vs. @ @ mm , p = @ ) and binary restenosis rate ( @ % vs. @ % , p = @ ) were very low and similar in both groups .

24412457

results

Clinical follow-up ( median @ days ) was obtained in all ( @ % ) patients .

24412457

results

Occurrences of the combined clinical outcome measure ( cardiac death , myocardial infarction , and target vessel revascularization ; @ % vs. @ % ; hazard ratio -LSB- HR -RSB- : @ ; @ % CI : @ to @ , p = @ ) and the need for target vessel revascularization ( @ % vs. @ % ; HR : @ : @ % CI : @ to @ , p = @ ) were similar in the @ groups .

24412457

conclusions

In patients with BMS-ISR , both DEB and EES provided excellent clinical results with a very low rate of clinical and angiographic recurrences .

24412457

conclusions

However , compared with DEB , EES provide superior late angiographic findings .

24412457

conclusions

( Restenosis Intra-stent of Bare Metal Stents : Paclitaxel-eluting Balloon vs. Everolimus-eluting Stent -LSB- RIBS V -RSB- ; NCT@ ) .

25367150

background

Irregularity measures have been suggested as risk indicators in patients with atrial fibrillation ( AF ) ; however , it is not known to what extent they are affected by commonly used rate-control drugs .

25367150

background

We aimed at evaluating the effect of metoprolol , carvedilol , diltiazem , and verapamil on the variability and irregularity of the ventricular response in patients with permanent AF .

25367150

results

Sixty patients with permanent AF were part of an investigator-blind cross-over study , comparing @ rate-control drugs ( diltiazem , verapamil , metoprolol , and carvedilol ) .

25367150

results

We analyzed five @-minute segments per patient : baseline and the @ drug regimens .

25367150

results

On every segment , heart rate ( HR ) variability and irregularity of RR series were computed .

25367150

results

The variability was assessed as standard deviation , pNN@ , pNN@ , pNN@ , and rMSSD .

25367150

results

The irregularity was assessed by regularity index , approximate ( ApEn ) , and sample entropy .

25367150

results

A significantly lower HR was obtained with all drugs , the HR was lowest using the calcium channel blockers .

25367150

results

All drugs increased the variability of ventricular response in respect to baseline ( as an example , rMSSD : baseline @ @ milliseconds , carvedilol @ @ milliseconds ; P < @ vs. baseline , metoprolol @ @ milliseconds ; P < @ vs. baseline , verapamil @ @ ; P < @ vs. baseline , diltiazem @ @ milliseconds ; P < @ vs. baseline and all other drugs ) .

25367150

results

Only - blockers significantly increased the irregularity of the RR series ( as an example , ApEn : baseline @ @ , carvedilol @ @ ; P < @ vs. baseline , metoprolol @ @ ; P < @ vs. baseline , verapamil @ @ ns , diltiazem @ @ ns ) .

25367150

conclusions

Modification of AV node conduction by rate-control drugs increase RR variability , while only - blockers affect irregularity .

24793028

objective

Among patients with quiescent ulcerative colitis ( UC ) , lower fecal concentrations of calprotectin are associated with lower rates of relapse .

24793028

objective

We performed an open-label , randomized controlled trial to investigate whether increasing doses of mesalamine reduce concentrations of fecal calprotectin ( FC ) in patients with quiescent UC .

24793028

methods

We screened @ patients with UC in remission on the basis of Simple Clinical Colitis Activity Index scores , FC > @ g/g , and intake of no more than @ g/day mesalamine .

24793028

methods

Participants taking mesalamine formulations other than multimatrix mesalamine were switched to multimatrix mesalamine ( @ g/day ) for @ weeks ; @ participants were then randomly assigned ( @:@ ) to a group that continued its current dose of mesalamine ( controls , n = @ ) or a group that increased its dose by @ g/day for @ weeks ( n = @ ) .

24793028

methods

The primary outcome was continued remission with FC < @ g/g .

24793028

methods

Secondary outcomes were continued remission with FC < @ g/g or < @ g/g ( among patients with pre-randomization values above these levels ) .

24793028

results

The primary outcome was achieved by @ % of controls and @ % of the dose escalation group ( P = @ ) .

24793028

results

More patients in the dose escalation group reduced FC to below @ g/g ( P = @ ) and @ g/g ( P = @ ) .

24793028

results

Among the patients who were still in remission after the randomization phase , clinical relapse occurred sooner in patients with FC > @ g/g compared with those with FC < @ g/g ( P = @ ) .

24793028

conclusions

Among patients with quiescent UC and increased levels of FC , increasing the dose of mesalamine by @ g/day reduced fecal concentrations of calprotectin to those associated with lower rates of relapse .

24793028

conclusions

Clinicaltrials.gov number : NCT@ .

26227186

background

Despite standard statin therapy , a majority of patients retain a high `` residual risk '' of cardiovascular events .

26227186

objective

The aim of this study was to evaluate the effects of ezetimibe plus atorvastatin versus atorvastatin monotherapy on the lipid profile and coronary atherosclerosis in Japanese patients who underwent percutaneous coronary intervention ( PCI ) .

26227186

methods

This trial was a prospective , randomized , controlled , multicenter study .

26227186

methods

Eligible patients who underwent PCI were randomly assigned to atorvastatin alone or atorvastatin plus ezetimibe ( @ mg ) daily .

26227186

methods

Atorvastatin was uptitrated with a treatment goal of low-density lipoprotein cholesterol ( LDL-C ) < @ mg/dl .

26227186

methods

Serial volumetric intravascular ultrasound was performed at baseline and again at @ to @ months to quantify the coronary plaque response in @ patients .

26227186

results

The combination of atorvastatin/ezetimibe resulted in lower levels of LDL-C than atorvastatin monotherapy ( @ @ mg/dl vs. @ @ mg/dl ; p < @ ) .

26227186

results

For the absolute change in percent atheroma volume ( PAV ) , themean difference between the @ groups ( -@ % ; @ % confidence interval -LSB- CI -RSB- : -@ % to @ % ) did not exceedthe pre-defined noninferiority margin of @ % , but the absolute change in PAV did show superiority for the dual lipid-lowering strategy ( -@ % ; @ % CI : -@ % to -@ % vs. -@ % ; @ % CI : -@ % to @ % with atorvastatin alone ; p = @ ) .

26227186

results

For PAV , a significantly greater percentage of patients who received atorvastatin/ezetimibe showed coronary plaque regression ( @ % vs. @ % ; p = @ ) .

26227186

results

Both strategies had acceptable side effect profiles , with a low incidence oflaboratory abnormalities and cardiovascular events .

26227186

conclusions

Compared with standard statin monotherapy , the combination of statin plus ezetimibe showed greater coronary plaque regression , which might be attributed to cholesterol absorption inhibition-induced aggressive lipid lowering .

26227186

conclusions

( Plaque Regression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by Intravascular Ultrasound -LSB- PRECISE-IVUS -RSB- ; NCT@ ) .